Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Orexo and Janssen Pharmaceuticals, formerly Ortho-McNeil-Janssen Pharmaceuticals, and Janssen Pharmaceutica, have terminated their research collaboration and license agreement regarding the OX-CLI and OX-ESI programs.
Subscribe to our email newsletter
A third, undisclosed Janssen program was also terminated.
Each party has regained all commercial rights for its respective drug discovery programs.
The OX-CLI and OX-ESI programs, focusing on discovering and developing innovative new treatments for asthma, chronic obstructive pulmonary disease and other inflammatory diseases, will be closed.